Literature DB >> 10933453

X-linked adrenoleukodystrophy: first report of the Italian Study Group.

A Di Biase1, S Salvati, C Avellino, M Cappa, E Bertini, I Moroni, M Rimoldi, G Uziel.   

Abstract

In this paper we report Italian data on X-linked adrenoleukodystrophy (ALD) collected from 1985 to 1997. This disease appears to be the most common of the peroxisomal disorders and is associated with a functional defect of the peroxisomal very long chain fatty acid (VLCFA) oxidation. In Italy 117 cases have been recognized, but many cases may be unrecognized due to the heterogeneous clinical manifestations that vary from mild to very severe forms. To control the devastating course of this disease two therapeutic approaches are under evaluation: bone marrow transplantation (BMT) and dietary treatment based on a mixture of glyceroyl trioleate (GTO) and glyceroyl trierucate (GTE). Our experience of 68 subjects submitted to dietary treatment shows that almost all patients with signs of cerebral involvement at the beginning of treatment worsened or died, patients with the milder form, adrenomyeloneuropathy (AMN), remained stable, while 4 of the 15 presymptomatic subjects developed neurological signs of the disease. In recent years a more accurate selection of patients and donors for BMT has given favourable results, but some strict criteria should be respected.

Entities:  

Mesh:

Year:  1998        PMID: 10933453     DOI: 10.1007/bf00713859

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  21 in total

1.  Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation.

Authors:  P Aubourg; S Blanche; I Jambaqué; F Rocchiccioli; G Kalifa; C Naud-Saudreau; M O Rolland; M Debré; J L Chaussain; C Griscelli
Journal:  N Engl J Med       Date:  1990-06-28       Impact factor: 91.245

2.  Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels.

Authors:  W B Rizzo; M W Phillips; A L Dammann; R T Leshner; S S Jennings; J Avigan; V K Proud
Journal:  Ann Neurol       Date:  1987-03       Impact factor: 10.422

3.  Leukodystrophy incidence in Germany.

Authors:  P Heim; M Claussen; B Hoffmann; E Conzelmann; J Gärtner; K Harzer; D H Hunneman; W Köhler; G Kurlemann; A Kohlschütter
Journal:  Am J Med Genet       Date:  1997-09-05

4.  Bone marrow transplant in adrenoleukodystrophy.

Authors:  H W Moser; P J Tutschka; F R Brown; A E Moser; A M Yeager; I Singh; S A Mark; A A Kumar; J M McDonnell; C L White
Journal:  Neurology       Date:  1984-11       Impact factor: 9.910

5.  High dose immunoglobulin IV treatment in adrenoleukodystrophy.

Authors:  M Cappa; E Bertini; P del Balzo; P Cambiaso; A Di Biase; S Salvati
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

6.  Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro.

Authors:  R W Whitcomb; W M Linehan; R A Knazek
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

7.  The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications.

Authors:  J M Powers; Y Liu; A B Moser; H W Moser
Journal:  J Neuropathol Exp Neurol       Date:  1992-11       Impact factor: 3.685

8.  Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids.

Authors:  H W Moser; A B Moser; K K Frayer; W Chen; J D Schulman; B P O'Neill; Y Kishimoto
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

9.  Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy.

Authors:  G Uziel; E Bertini; P Bardelli; M Rimoldi; M Gambetti
Journal:  Dev Neurosci       Date:  1991       Impact factor: 2.984

Review 10.  Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome.

Authors:  H W Moser
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

View more
  3 in total

1.  A mixture of oleic, erucic and conjugated linoleic acids modulates cerebrospinal fluid inflammatory markers and improve somatosensorial evoked potential in X-linked adrenoleukodystrophy female carriers.

Authors:  Marco Cappa; Carla Bizzarri; Anna Petroni; Gianfranca Carta; Lina Cordeddu; Massimiliano Valeriani; Catello Vollono; Loredana De Pasquale; Milena Blasevich; Sebastiano Banni
Journal:  J Inherit Metab Dis       Date:  2011-12-22       Impact factor: 4.982

Review 2.  The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis.

Authors:  Christoph Wiesinger; Florian S Eichler; Johannes Berger
Journal:  Appl Clin Genet       Date:  2015-05-02

3.  Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.

Authors:  Alice Bessey; James B Chilcott; Joanna Leaviss; Anthea Sutton
Journal:  Orphanet J Rare Dis       Date:  2018-10-11       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.